EMA Authorised: Darzalex (daratumumab)

View source ↗

Summary

EMA authorised Darzalex (daratumumab) for use in multiple myeloma with orphan designation and accelerated assessment.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• DARZALEX (daratumumab)

Snippet

Status: Authorised. Therapeutic area: Multiple Myeloma. Decision date: 11/06/2026. Orphan medicine. Accelerated assessment